UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

Core Insights - UNITY Biotechnology, Inc. is set to present 36-week data from the ASPIRE Phase 2B study at the ARVO 2025 Annual Meeting, focusing on therapeutics aimed at diseases of aging [1] - The presentation will cover the safety and efficacy of the senolytic candidate UBX1325 for Diabetic Macular Edema, highlighting findings from the BEHOLD Phase 2 and ASPIRE Phase 2B trials [2] Company Overview - UNITY is developing a new class of therapeutics designed to slow, halt, or reverse diseases associated with aging, with a current focus on age-related ophthalmologic and neurologic diseases [3]